First Tracks Biotherapeutics (TRAX) Q2 2026 earnings summary

Executive summary

• Completed spin-off from AnaptysBio in April 2026, establishing as an independent, publicly traded clinical-stage biotech focused on antibody therapies for autoimmune and inflammatory diseases.

• Raised $80 million in gross proceeds from a private placement concurrent with the spin-off.

• Pipeline includes ANB033 (celiac disease, eosinophilic esophagitis), rosnilimab (rheumatoid arthritis), and ANB101 (inflammatory diseases).

• Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease; top-line data expected Q4 2026; FDA granted Fast Track designation for ANB033.

• Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-line data expected Q3 2027.

Financial highlights

• Cash and cash equivalents were $168.0 million as of June 30, 2026, down from $238.2 million at December 31, 2025.

• Net loss for Q2 2026 was $33.4 million, or $0.95 per share, compared to $42.4 million, or $1.47 per share, in Q2 2025.

• Operating expenses for Q2 2026 were $34.9 million, down from $45.9 million in Q2 2025.

• Research and development expenses were $25.6 million for Q2 2026, down from $39.3 million in Q2 2025.

• General and administrative expenses were $9.3 million for Q2 2026, up from $6.6 million in Q2 2025.

Outlook and guidance

• Management believes current cash and investments will fund operations for at least the next 12 months; cash runway projected into Q2 2028, supporting expansion into two additional indications in H1 2027.

• Top-line data from Cohort 1 of Phase 1b ANB033 in celiac disease expected Q4 2026; Cohort 2 data in Q1 2027.

• Phase 1b data for ANB033 in eosinophilic esophagitis anticipated Q3 2027.

• Expects continued operating losses as clinical programs advance and no near-term product revenue.

• Plans to seek additional financing or strategic investments as needed to support expansion and clinical development.